MNOV vs. SCYX, MURA, KRON, CALC, ANVS, VHAQ, KZR, JAGX, ELDN, and YS
Should you be buying MediciNova stock or one of its competitors? The main competitors of MediciNova include SCYNEXIS (SCYX), Mural Oncology (MURA), Kronos Bio (KRON), CalciMedica (CALC), Annovis Bio (ANVS), Viveon Health Acquisition (VHAQ), Kezar Life Sciences (KZR), Jaguar Health (JAGX), Eledon Pharmaceuticals (ELDN), and YS Biopharma (YS). These companies are all part of the "pharmaceutical preparations" industry.
MediciNova (NASDAQ:MNOV) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.
SCYNEXIS has a consensus target price of $15.00, indicating a potential upside of 747.46%. Given SCYNEXIS's higher probable upside, analysts plainly believe SCYNEXIS is more favorable than MediciNova.
SCYNEXIS received 296 more outperform votes than MediciNova when rated by MarketBeat users. Likewise, 70.24% of users gave SCYNEXIS an outperform vote while only 52.25% of users gave MediciNova an outperform vote.
SCYNEXIS has a net margin of 47.84% compared to MediciNova's net margin of 0.00%. SCYNEXIS's return on equity of 156.27% beat MediciNova's return on equity.
In the previous week, MediciNova had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 2 mentions for MediciNova and 1 mentions for SCYNEXIS. MediciNova's average media sentiment score of 0.74 beat SCYNEXIS's score of 0.49 indicating that MediciNova is being referred to more favorably in the media.
9.9% of MediciNova shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 16.9% of MediciNova shares are owned by insiders. Comparatively, 4.4% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
SCYNEXIS has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.
MediciNova has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.
Summary
SCYNEXIS beats MediciNova on 13 of the 17 factors compared between the two stocks.
Get MediciNova News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MediciNova Competitors List
Related Companies and Tools
